Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

Opiate Induced Respiratory Depression Clinical Trial

Official title: Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

Status Active, not recruiting

Clinical Trial Summary

The study is an investigation to assess the capacity of ascending doses of CX1739 to antagonize the respiratory depressive effect of remifentanil. The study will also investigate whether ascending doses of CX1739 reduce the analgesic effect of remifentanil or alter the BIS measure of sedation and will evaluate the safety of CX1739 when used in conjunction with remifentanil.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Opiate Induced Respiratory Depression
• Respiratory Insufficiency

• NCT number: NCT02735629
• Study type: Interventional
• Source: RespireRx
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 2016
• Completion date: September 2016